The trastuzumab-based chemotherapy exhibited a survival benefit for human epidermal growth factor receptor-2 (HER2)-positive GC patients in the ToGA trial7, where an anti-HER2 targeted strategy was proposed as a standard approach for HER2-positive GC patients. The gene discussed is ERBB2; the disease is gastric cancer.